Recombinant Human SLAMF2 (C-mFc)

Description

EnkiLife provides the Recombinant Human SLAMF2 (C-mFc) protein,aslo know as CD48 antigen,B-lymphocyte activation marker BLAST-1,BCM1 surface antigen,Leukocyte antigen MEM-102,TCT.1,CD48,BCM1,BLAST1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human SLAM Family Member 2 is produced by our Mammalian expression system and the target gene encoding Gln27-Ser220 is expressed with a mouse IgG1 Fc tag at the C-terminus.Accession:P09326. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:48.9 KDa. Background:CD48 antigen, also known as B-lymphocyte activation marker BLAST-1, BCM1 surface antigen, Leukocyte antigen MEM-102, TCT.1, CD48, BCM1,and BLAST1, CD48 contains one Ig-like C2-type domain and one Ig-like V-type domain, but does not have a transmembrane domain, however, but is held at the cell surface by a GPI anchor via a C-terminal domain which maybe cleaved to yield a soluble form of the receptor. CD48 may facilitate interaction between activated lymphocytes and be involved in regulating T-cell activation. CD48 plays a vital role as an environmental sensor for regulating progenitor cell numbers and inhibiting tumor development. It is suggested that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against multiple myeloma.